Accessibility Menu
Immutep logo

Immutep(ASX) IMM

Market CapA$76.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-98%
5 Year-89%
1 Year-79%
1 Month-5%
A$0.05
-1.92%
-0.00Today
Immutep last closing stock price
MetricPriceDate
Last closeAUD 0.052026-08-13
Immutep stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.04%AUD 0.052026-08-06
1 month-5.45%AUD 0.062026-07-14
3 month-13.33%AUD 0.062026-05-15
Year to date-87.47%AUD 0.422025-12-31
1 year-79.2%AUD 0.252025-08-13
3 year-82.07%AUD 0.292023-08-14
5 year-89.49%AUD 0.502021-08-13
Since inception-98.11%AUD 2.751992-01-02

Immutep Financials at a Glance

Market Cap

A$76.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$10.86M

Net Income (TTM)

-A$127.78M

EPS (TTM)

-A$0.06

P/E Ratio

-0.91

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Price

A$0.05

Volume

1,226,562

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.05

52-Week Range

A$0.03 - A$0.47

Estimated Earnings Date

Sep 2, 2026

IMM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immutep

Immutep Limited is a biotechnology company focused on developing innovative immunotherapies targeting Lymphocyte Activation Gene-3 (LAG-3) for cancer and autoimmune diseases. The company is advancing several clinical trials, including its lead product candidate, eftilagimod alfa, which aims to treat various cancers.

Products and Services
  • Eftilagimod alfa (IMP321) for cancer treatment
  • TACTI-004 in phase III for non-small cell lung cancer
  • IMP761 in phase I for autoimmune diseases
Growth Outlook
  • Recent revenue of AUD 4.08 million indicates potential market traction
  • Strong cash position with AUD 72.75 million in cash and equivalents
  • Multiple ongoing clinical trials could lead to significant product advancements
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 15.5 million
  • Operating loss of AUD 48 million in the latest quarter
  • Current ratio of 2.97 suggests strong liquidity position
Immutep Limited is positioned in the biotechnology sector, focusing on innovative therapies that leverage the immune system to combat diseases. The company’s lead candidate, eftilagimod alfa, is currently undergoing clinical trials, which could pave the way for future revenue streams. The recent quarterly revenue of AUD 4.08 million reflects a growing interest in its products, while the strong cash reserves provide a buffer for ongoing research and development efforts. With several clinical trials in progress, the potential for significant advancements in treatment options remains promising. Investors may find the company's focus on LAG-3 immunotherapies and its strategic partnerships with major pharmaceutical companies noteworthy as it navigates the competitive landscape of biotechnology.
AI Generated • Aug 8, 2026

Industry

Biotechnology

CEO

Marc Voigt, MBA

Headquarters

Sydney, NSW 2000, AU

IMM Financials

Key Financial Metrics (TTM)

Gross Margin

-522.59%

Operating Margin

-2052.18%

Net Income Margin

-1404.13%

Return on Equity

-69.20%

Return on Capital

-87.03%

Return on Assets

-57.01%

Earnings Yield

-1.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$76.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.47B

Volume

1.23M

Avg. Volume

16.13M

Financials (TTM)

Gross Profit

-A$72.79M

Operating Income

-A$218.93M

EBITDA

-A$132.07M

Operating Cash Flow

-A$98.19M

Capital Expenditure

-A$187.79K

Free Cash Flow

-A$98.38M

Cash & ST Invst.

A$99.13M

Total Debt

A$2.16M

Immutep Performance Analysis

Immutep annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 170,369N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Immutep sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-18.0%
Q22024-12-3181.9%
Q42025-06-30-39.8%
Q22025-12-31115.2%
Immutep annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.04N/A
20232023-06-30AUD -0.0419.7%
20242024-06-30AUD -0.04-19.6%
20252025-06-30AUD -0.0418.5%
Immutep sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-301.1%
Q22024-12-3113.0%
Q42025-06-30-74.0%
Q22025-12-31-13.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$4.08M

+93.3%

Gross Profit

A$2.95M

+116.1%

Gross Margin

72.34%

N/A

Market Cap

A$76.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.34M

N/A

Employees

57

N/A

Net Income

-A$44.86M

-111.3%

EBITDA

-A$46.84M

-111.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$99.13M

-4.4%

Total Debt

A$2.16M

+33.7%

Accounts Receivable

A$37.52M

+510.4%

Inventory

A$0.00

N/A

Long Term Debt

A$1.90M

+35.2%

Short Term Debt

A$260.00K

-38.1%

Return on Assets

-57.01%

N/A

Return on Invested Capital

-1.22%

N/A

Free Cash Flow

-A$28.74M

-414.1%

Operating Cash Flow

-A$28.65M

-412.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAR.AXParadigm Biopharmaceuticals Limited
A$0.18+0.00%
BOT.AXBotanix Pharmaceuticals Limited
A$0.02+0.00%
EBR.AXEBR Systems, Inc.
A$0.30-1.67%
DXB.AXDimerix Limited
A$0.30+0.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About IMM

What is the current price of Immutep?

Immutep is trading at A$0.05 per share.

What is the 52-week range for Immutep?

Over the past 52 weeks, Immutep has traded between A$0.03 and A$0.47.

How much debt does Immutep have?

As of the most recent reporting period, Immutep reported total debt of A$1.63M.

How much cash does Immutep have on hand?

Immutep reported A$67.41M in cash and cash equivalents in its most recent financial results.

What is Immutep’s dividend yield?

Immutep does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.